| ALIGOS THERAPEUTICS |
| USA |
| Gesundheit |
| US01626L2043 / A40LQ4 |
| 5WK0 (Frankfurt) / ALGS (NASDAQ) |
| FRA:5WK0, ETR:5WK0, 5WK0:GR, NASDAQ:ALGS |
| - |
| https://aligos.com/ |
|
Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for liver and viral diseases. The company targets unmet medical needs in areas such as chronic hepatitis B, metabolic ..
>Volltext.. |
| 30.24 Mio. EUR |
| -13.65 Mio. EUR |
| 4.11 Mio. EUR |
| -82.7 Mio. EUR |
| -78.97 Mio. EUR |
| -7.61 EUR |
| 3.81 Mio. EUR |
| 26.36 Mio. EUR |
| -74.07 Mio. EUR |
| 2.36 |
| 34.73% |
| -58.79% |
| - |
| - |
| - |
| - |
| ALIGOS |
| 07.07.26 |
|